CMS finds Mylan overcharged Medicaid for EpiPens for years

The Centers for Medicare & Medicaid Services said this week that Mylan Pharmaceuticals (NSDQ:MYL) has been overcharging Medicaid for its EpiPen auto-injector for years, despite being warned that it should have paid bigger rebates.

CMS said that between 2011 and 2015, Medicaid spent $797 million on the epinephrine auto-injector after deducting rebates, marking the 1st time the federal agency has revealed how much it spent on the device. CMS revealed last week that Mylan misclassified the device as a generic, allowing the company to pay a 13% rebate instead of the 23% allocated for brand-name products.

Get the full story at our sister site, Drug Delivery Business News. 

The post CMS finds Mylan overcharged Medicaid for EpiPens for years appeared first on MassDevice.

from MassDevice http://ift.tt/2cZKxu8